in 11-␤ hydroxysteroid dehydrogenase type 1 (11␤-HSD1, encoded by HSD11B1) have been reported to be associated with obesity-related cardiovascular risk factors, such as type II diabetes and hypertension. Left ventricular hypertrophy (LVH) is an independent risk factor for cardiovascular death associated with these factors but has significant additional heritability, the cause of which is undetermined. The 11␤-HSD1 is believed to maintain tonic inhibition of the mineralocorticoid receptor in cardiomyocytes, and mineralocorticoid receptor activation is involved in the pathophysiology of LVH. We assessed the association between polymorphisms in the HSD11B1 gene and left ventricular mass (LVM) in 248 families ascertained through a proband with hypertension. Methods and Results-LVM was measured by electrocardiography and echocardiography in 868 and 829 participants, respectively. Single-nucleotide polymorphisms (SNPs) tagging common variation in the HSD11B1 gene were genotyped by mass spectrometry. The rs846910 SNP, which lies in the flanking region 5Ј to exon 1B of HSD11B1, was associated with LVM both by electrocardiography (Ϸ5% lower LVM per copy of the rare allele, Pϭ0.02) and by echocardiography (Ϸ10% lower LVM per copy of the rare allele, Pϭ0.003). Genotype explained 1% to 2% of the population variability in LVM, or approximately 5% of the heritable fraction. There were no significant associations between any HSD11B1 SNP and blood pressure or body mass index that could have confounded the association with LVM. Conclusions-Genotype at HSD11B1 has a small, but significant effect on LVM, apparently independently of any effect on obesity-related traits. These findings suggest a novel action of 11␤-HSD1 in the human cardiomyocyte, which may be of therapeutic importance. (Circ Cardiovasc Genet. 2011;4:156-162 .) The online-only Data Supplement is available at http://circgenetics.ahajournals.org/cgi/content/full/CIRCGENETICS.110.958496/DC1.
T he microsomal enzyme 11-␤ hydroxysteroid dehydrogenase (11␤-HSD1) in humans generates the active glucocorticoid cortisol from inactive cortisone. The protein is strongly expressed in glucocorticoid target tissues, including in the liver where it promotes gluconeogenesis and in adipose tissue where it promotes adipocyte differentiation. A number of lines of evidence point to a key role for 11␤-HSD1 in the pathophysiology of metabolic disease. 1 Transgenic mice overexpressing 11␤-HSD1 in adipose tissue develop all the major features of metabolic syndrome, 2 and 11␤-HSD1 knockout mice are resistant to diabetes and obesity. 3, 4 Preclinical data on specific 11␤-HSD1 inhibitors indicate their capacity to improve all aspects of the metabolic syndrome in mouse models, including a beneficial effect on atherosclerosis susceptibility, 5 and clinical trials to test similar agents in humans are at an advanced stage. The 11␤-HSD1 has important roles in tissues other than liver and adipose tissue.
Recent data indicate that 11␤-HSD1 mediates insulin resistance in skeletal muscle 6 and is involved in regulating insulin and glucagon secretion in pancreatic islets. 7 The 11␤-HSD1 also is expressed at high levels in cardiomyocytes, where it is believed that local generation of cortisol by 11␤-HSD1 is principally responsible for the occupation of mineralocorticoid receptors (MRs) in the cardiomyocyte by glucocorticoid. 8 The MR in the cardiomyocyte, as in other tissues, has equal affinity for cortisol and aldosterone, and under physiological conditions, local concentrations of glucocorticoid are sufficient to fully occupy the receptor. MR activation by aldosterone plays an important role in the development of pathological left ventricular hypertrophy (LVH), which can be ameliorated by the specific aldosterone antagonist eplerenone. 9, 10 Moreover, cardiac-specific overexpression in transgenic mice of the 11␤-HSD2, which catalyzes the reverse reaction to 11␤-HSD1 in which cortisol is converted to cortisone, causes cardiac hypertrophy and fibrosis. 11 Cardiac hypertrophy induced by chronic intermittent hypoxia in the rat also is associated with an upregulation of cardiac 11␤-HSD2 relative to 11␤-HSD1. 12 Therefore, strong evidence exists with regard to the importance of prereceptor regulation of glucocorticoid signaling in the development of cardiac hypertrophy in rodents, although this remains an open question in humans.
Clinical Perspective on p 162
LVH is a strong independent predictor of cardiovascular morbidity and mortality. Previous data from a number of sources, including our own work, have shown that left ventricular mass (LVM), considered a quantitative trait, has substantial heritability whether measured by electrocardiography or echocardiography. 13 However, the genetic differences accounting for this heritability between individuals remain largely unknown. We explored the hypothesis that variation in the HSD11B1 gene, which encodes 11␤-HSD1, is associated with differences in LVM in a family-based association study. The study population was enriched for higher LVM, as families were ascertained from a hypertensive proband. Families were intensively phenotyped for blood pressure, the most important potential confounder, using ambulatory monitoring.
Methods
The collection strategy of this family study has been described previously. 14 Briefly, British families of Caucasian European (CEU) ancestry were ascertained in 1993 to 1996 through a proband with essential hypertension. The following criteria defined eligibility as a proband: a mean systolic blood pressure Ͼ140 mm Hg and a mean diastolic blood pressure Ͼ90 mm Hg on daytime ambulatory blood pressure monitoring, or Ͼ3 office blood pressure readings Ͼ160 mm Hg systolic and 95 mm Hg diastolic, or treatment with Ն2 antihypertensive drugs. These relatively stringent criteria were applied to provide maximum assurance that probands were at the upper end of the population blood pressure distribution. Secondary hypertension was excluded using the standard screening protocol applied in the hypertension clinic. To be suitable for the study, families were required to consist of at least 3 clinically assessable siblings willing to give blood for DNA analysis if at least 1 parent of the sibship was also available to give blood and to consist of at least 4 assessable siblings if no parent was available for DNA analysis. Sibships were recruited either in the generation of the proband or his or her offspring. Where members of the sibship were found to be hypertensive, families were extended and the spouses and offspring of hypertensive siblings collected. Thus, the family collection included some extended families, although most were nuclear families, and the majority of the individuals in the family collection had blood pressures within the conventionally accepted normal range. The study received ethical clearance from the appropriate review committees and corresponded with the principles of the Declaration of Helsinki. All participants gave informed consent to participate in the study.
Blood pressure was measured using ambulatory monitoring, using the A&D TM2421 monitor according to a previously described protocol, 15 for a 24-hour period in all subjects willing to undergo monitoring. A full clinical history was taken, which included medical history and lifestyle factors, including consumption of alcohol and tobacco and habitual physical exercise. Anthropometric measurements, including height, weight, and waist and hip circumferences, were performed according to standard methods. DNA was extracted from blood samples using standard methods.
Families were recalled for additional cardiovascular phenotyping in 1997 to 1999, at which time electrocardiographic and echocardio-graphic measurements were made. Standard resting 12-lead ECGs were acquired using a Nihon Kohden cardiofax 3-channel recorder at 25 mm/s and 10 mm/mV with no filter. The ECGs were scored manually by 1 experienced reader, and the following measurements were made: QRS duration in milliseconds, R-wave amplitude in standard lead aVL and the greater of precordial leads V 5 or V 6 , and S-wave amplitude in precordial leads V 1 and V 3 . Amplitude measurements were made in millivolts from 3 consecutive complexes to minimize beat-to-beat variation caused by respiration. Electrocardiographic LVM in grams was calculated using the following formulas: LVMϭ0.026ϫ(RaVLϩSV 3 )ϩ(1.25ϫweight)ϩ34.4 for men and LVMϭ0.020ϫ(RaVLϩSV 3 )ϩ(1.12ϫweight)ϩ36.2 for women. 16 Sokolow-Lyon voltage was calculated as the sum of SV 1 and RV 5/6 . A reproducibility study was performed on 10 randomly selected subjects for whom 2 readers blinded to subject identity scored the ECGs on 2 separate occasions. Subjects with ECG evidence of pathological Q waves, complete right or left bundle branch block, or an electronic pacemaker were excluded from the ECG analyses.
Two-dimensional M-mode echocardiograms were obtained from each subject by 1 of 2 expert sonographers with a 3.5-MHz transducer interfaced with a Sonos 5500 machine (Hewlett-Packard; Andover, MA) in accordance with methods of the American Society of Echocardiography. The M-mode images were recorded on digital disk and read by 1 physician (B.M.M.) on an offline workstation using a customized Medarchive software program (Selectronic Ltd; Berkshire, UK). The echocardiographic measurements were analyzed on 3 successive heartbeats, and values were averaged. Measurements of wall thickness and ventricular diameter for the calculation of LVM were made in random order without regard to family relationships. The following LV dimensions were measured at end diastole: interventricular septal thickness (IVS d ), posterior wall thickness (LVPW d ), and internal diameter (LVID d ). Each structure had to be measurable for the echocardiogram to be considered technically adequate for study. LVM (in grams) was calculated according to the corrected American Society of Echocardiography formula as follows: 0.8ϫ{1.04ϫ[(IVS d ϩLVID d ϩLVPW d ) 3 ϪLVID d 3 ]}ϩ0.6. Regional wall thickness (RWT) was calculated using the following formula: 2ϫLVPW d /LVID d . A reproducibility study was performed on 10 randomly selected subjects in whom 2 readers blind to subject identity scored the echocardiograms on 2 separate occasions. Subjects in whom technically satisfactory echocardiograms could not be obtained, with significant valvular heart disease, or with echocardiographic abnormalities consistent with previous myocardial infarction were excluded from the echocardiographic analyses.
TagSNPs within the HSD11B1 gene and 15 Kb in either direction (to incorporate close-range upstream and downstream regulatory sequences) were identified by reference to the Phase II SNP data from the HapMap CEU samples of Northern and Western European ancestry (http://www.hapmap.org). The pairwise tagging strategy was implemented with the Tagger utility in the Haploview software package, with the parameters r 2 Ͼ0.8 and minor allele frequency Ն0.05. Seven tagSNPs were required; these captured the information from 22 SNPs throughout the gene at a mean r 2 of 0.95. Selected SNPs, their location in the region, and the linkage disequilibrium pattern across the gene (from HapMap data) are shown in the Figure. Multiplex genotyping was carried out using the Sequenom matrixassisted laser desorption/ionization-time of flight instrument as previously described. 17 Forward and reverse primers and extension primers for each genotyping reaction are provided in the online-only Data Supplement tables. Control subjects of known genotype were included in every plate, and 100 randomly selected samples were genotyped twice for each polymorphism. Genotyping was carried out blinded to phenotypic information.
Mendelian inheritance of all the genotypes and Hardy-Weinberg equilibrium for each marker were checked using PEDSTATS. 18 Additional checks based on unlikely recombination patterns within families were carried out using the error checking option in the analysis program MERLIN. 19 Errors were corrected when possible by reference to the raw genotyping data, and when this was not possible, genotypes were excluded from analysis. Phenotypes were examined for normality; all variables required either log-transformation or square-root transformation to adequately conform to a normal distribution. Transformed phenotypes were adjusted for significant covariates through linear regression as previously described. 20 Briefly, age, age squared, sex, smoking, alcohol consumption, and habitual physical activity were considered as potential covariates of blood pressure and body mass index. Blood pressure was additionally adjusted for drug treatment in those taking antihypertensive medication, as previously described. 20 The same set of variables, with the addition of blood pressure and body mass index, were considered potential covariates of electrocardiographic and echocardiographic measurements of LVM. Covariates reaching statistical significance at PϽ0.05 were included in the final model. Additional detail regarding covariate adjustment is provided in the online-only Data Supplement. The logtransformed, covariate-adjusted residuals were entered into the quantitative trait genetic association analyses of LVM, which were performed using a variance-components approach that takes account of shared polygenic effects in members of the same pedigree, implemented as the likelihood ratio test option in MERLIN. 19 We tested an additive genetic model a priori; in cases where homozygotes for the rare allele were few, we also tested a dominant model.
Results
A total of 1425 subjects from 255 families were recruited into the study of whom 52.4% were women and 36.1% were hypertensive by our criteria. The median family size was 5 persons; 60% of families comprised between 4 and 6 genotyped and phenotyped members. Seventy-one percent of families were 2 generations, and 29% were 3 generations. Eighty-four percent of families had an assessable sibship in the generation of the proband, whereas 16% of families consisted of a proband and his or her nuclear family (spouse and children aged Ͼ18 years) only. ECGs and echocardiograms were obtained from 955 family members (449 men and 506 women), representing a 67% response rate to the invitation for the second phase of phenotyping. After excluding subjects with structural heart disease (nϭ69), technically inadequate echocardiograms (nϭ60), and electrocardiographic abnormalities (nϭ18), 868 and 829 subjects were eligible for the genetic analyses of electrocardiographic and echocardiographic phenotypes, respectively. Excluded subjects were older, more often hypertensive, diabetic, and men. The electrocardiographic analyses included 224 families (395 men and 473 women), and the echocardiographic analyses included 222 families (362 men and 467 women). The intrareader and interreader coefficients of variability for the ECG and echocardiogram measurements are provided in the online-only Data Supplement. Characteristics of the population for the phenotypes of interest are shown in Table 1 . Genotyping was successful at all SNPs in Ն95% of the population, and the estimated genotyping error rate was Ͻ1%. All markers were in Hardy-Weinberg equilibrium at the 5% significance level. Allele frequencies were similar to the HapMap data for the CEU population at all markers. Genotyping results for all SNPs are summarized in onlineonly Data Supplement Table 3 . There was an association between the rs846910 SNP situated 5Ј to exon 1b of HSD11B1 and both echocardiographic and electrocardiographic measurements of LVM after adjustment for potential confounders. The minor A allele of rs846910 was associated with both a lower IVS d (Pϭ0.001) and a LVPWS d (Pϭ0.004), resulting in a lower echocardiographic LVM (Pϭ0.003) and lower RWT (Pϭ0.006) ( Table 2 ). For each of these echocardiographic measurements, the fitted model implies that untransformed values were 7% to 10% lower per A allele, which in the case of LVM would translate to an Ϸ21-g lower LVM as measured by echocardiography per allele. Genotype at rs846910 accounted for between 1.12% and 1.60% of the population variability in the adjusted echocardiographically measured phenotypes, or Ϸ5% of the heritable fraction, which was between 24.6% and 27.0% for these phenotypes. Because AA homozygotes were infrequent, we also fitted a dominant model comparing GG homozygotes with (GAϩAA) individuals. Association between the presence of the A allele and echocardiographic measurements was confirmed under this model (0.003ϽPϽ0.019) ( Table 2) ; the estimated effect of the SNP and the contribution to the heritability on the phenotype were not materially different from those under the additive model. The echocardiography findings were corroborated by an association between ECG phenotypes and the rs846910 genotype, albeit weaker than the association with the echocardiogram phenotypes. Genotype was associated with a Ϸ5% lower LVM measured by ECG per A allele (Pϭ0.015) ( Table 2) , although this result was no longer significant under the dominant model. Similarly, there was a trend toward a lower Sokolow-Lyon voltage with the A allele, although this failed to reach statistical significance (Pϭ0.053, additive model) ( Table 2 ). These findings are in keeping with what might be expected given the less-precise measurement of LVM that is obtained using ECG compared to echocardiogram. No other SNPs had a significant association with echocardiogram-or ECGmeasured LVM (PϾ0.05 for all). If a Bonferroni correction for multiple testing of 7 SNPs is applied to the data, which is acknowledged to be overconservative, the associations between genotype and echocardiographic LVM remain significant. Finally, to ensure that our result did not arise from a Abbreviations as in Table 1 .
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confounded association between HSD11B1 genetic variation and either blood pressure or body mass index, which are risk factors for LVH, we tested for association between these phenotypes and SNP genotypes; no association was present (PϾ0.05 for all).
Discussion
In the present study, we have shown an association between genotype at a promoter polymorphism of HSD11B1 and LVM. Echocardiographic LVM was 10.3% lower in heterozygote carriers of the rare A allele of the rs846910 SNP. Genotype accounted for only a small proportion of the total population variability (1.25%); however, this constituted a moderate contribution (5%) to the heritability of LVM in our family cohort. The association would be equivalent to an Ϸ20-g lower LVM, which is about one third of an SD in our population, in heterozygotes at rs846910. Although this effect is insufficiently large to advocate any role for HSD11B1 genotyping in stratifying risk of developing LVH, if multiple loci with similar-sized effects could be identified, genotyping at a panel of such SNPs would have the potential to assist in discriminating a cohort predisposed to the development of LVH. In the setting of hypertension, which is the principal risk factor for the development of LVH, consideration could then be given to more intensive blood pressure-lowering treatment in such patients. Our findings using echocardiographic measurements were corroborated by a less strong, but still significant association between LVM measured by ECG and rs846910 genotype. We anticipated any association with ECG measurements of LVM would be less strong than with echocardiogram measurements given the substantially inferior accuracy of LVM determination using ECG and, hence, higher levels of random error in the measurement. We did not find any associations between HSD11B1 genotypes and either blood pressure or body mass index that might have confounded the association with LVM. Our findings suggest that prereceptor glucocorticoid regulation by 11␤-HSD1 plays a significant role in the pathophysiology of LVH in humans. Previous studies conducted in this cohort of families showed that the study has power to detect genetic effects of a similar magnitude to that described here, 21 which subsequently have been replicated in other cohorts. 22 To our knowledge, no previous studies have investigated polymorphisms in the HSD11B1 gene for association with LVM. A number of previous studies have, however, investigated associations between such polymorphisms and other phenotypes, mainly those involved in cardiometabolic risk. Promoter variants in HSD11B1 have been associated with differential levels of gene transcription, and the presence of functional variants in the linkage disequilibrium block encompassing rs846910 has been established. 23, 24 Downstream effects of polymorphic variation in HSD11B1 on glucocorticoid metabolism were found in studies by Draper et al, 25 which used microsatellite markers, and more recently by Morales et al 26 in a Chilean population. Association between HSD11B1 polymorphisms and diabetes or insulin resistance were initially documented in the Pima Indians, 27 although these findings were not confirmed by other studies, 23, 28 including 1 in the Pima Indian population. 29 Association between HSD11B1 genotypes and body mass index has not been found in any of the studies in which it had been sought, 25, [27] [28] [29] although 1 of these studies found an association with waist-hip ratio. 25 Association with blood pressure was found in 1 study, 29 but this association was not confirmed in subsequent studies 28, 30 Previous candidate gene studies of HSD11B1 are summarized in online-only Data Supplement Table 4 . HSD11B1 has not emerged as a strong genetic risk factor for any of these phenotypes in the increasing number of genome-wide association studies in the literature. Taken together, no conclusive association between HSD11B1 polymorphisms and any clinical cardiovascular phenotype has been established thus far; however, weak effects, which would be detectable only in many thousands of patients, have not been ruled out.
We showed in the present study that lower LVM is associated with carriage of the minor A allele of rs846910. A haplotype carrying the A allele has been previously associated with higher 11␤-HSD1 mRNA levels and activity in Southern European whites, although an in vitro assay showed no direct effect of the rs846910 variant on gene expression. 24 In general, previous studies of cardiometabolic risk considered the A allele as a risk variant and higher transcriptional activity of HSD11B1 as a deleterious factor. By contrast, the present data suggest that somewhat higher levels of HSD11B1 expression in the cardiomyocyte (and therefore a shift in the dynamic equilibrium between cortisone and cortisol toward cortisol) may have a protective effect against the development of LVH because the allele associated in other studies with higher HSD11B1 expression was associated with lower echocardiographic and electrocardiographic measurements of LVM in our population.
To our knowledge, the present study provides the first evidence of the importance of prereceptor glucocorticoid regulation in determining cardiac mass. Our findings raise interesting questions about the mechanism involved. One possibility is that a balance between HSD11B1 and HSD11B2 expression in the cardiomyocyte influences prereceptor corticosteroid metabolism and MR activity and, thus, propensity to develop LVH. This notion is supported by data from the mouse model selectively overexpressing HSD11B2 in cardiomyocytes, which (perhaps unexpectedly given the role of HSD11B2 in inactivating cortisol) leads to cardiac hypertrophy. 11 However, at the mRNA level, HSD11B2 expression seems very much lower than HSD11B1 in normal human LV tissue; indeed, some previous investigations have found only HSD11B1 transcripts in the heart without evidence of HSD11B2 expression. [31] [32] [33] [34] In this context, it is unlikely that a relatively small effect of the haplotype involving rs846910 on HSD11B1 transcription would materially alter the balance between HSD11B1 and HSD11B2 activity in the heart, and thus, cardiac MRs at baseline probably are saturated by cortisol regardless of rs846910 genotype (in common with other nonepithelial tissues). However, upregulation of cardiac MR activity takes place in cardiac hypertrophy and failure; it is possible that enhanced local cortisol generation in carriers of the rs846910 A allele could, through a higher level of cardiomyocyte MR occupancy by cortisol rather than aldosterone, exert a protective effect on the initiation or progres-sion of cardiac hypertrophy that might be particularly important in the setting of hypertension. This model would predict that the consequences of MR occupancy by cortisol and aldosterone in the heart are different (in ways that are as yet unclear) and would be consistent with both our present results and the previous rodent models. Testing of these hypotheses will require further mechanistic studies to be undertaken.
The present study has certain limitations. Our results will require replication in additional cohorts, ideally loaded in a similar fashion to our study for the presence of hypertension. The recent EchoGen study 35 did not find a significant association between LVM and SNPs in HSD11B1 in a genome-wide association approach; it is possible that the relatively modest effect we describe here was insufficiently strong to reach genome-wide significance in that study, which of note enrolled chiefly normotensive individuals rather than those selected for hypertension. The minor allele frequency of rs846910 is only approximately 5% in whites, which suggests that replication may require the study of very large numbers of such individuals. Blood pressure and other covariates were determined at the first examination of our cohort and not repeated at the time the ECG and echocardiogram measurements were made; if there had been material changes in these covariates between the 2 time points, it could have biased our result toward the null.
Although the effect we describe is not sufficiently large to have clinical applicability, the mechanism we hypothesize to account for the result could have considerable clinical importance. The 11␤-HSD1 inhibitors are under intensive testing as potential agents to reduce cardiometabolic risk. If 11␤-HSD1 inhibition in the heart led to a greater risk of developing LVH, which is an independent risk factor for cardiovascular mortality, then the anticipated benefits of such agents could be considerably reduced. Echocardiographic surveillance of patients enrolled in clinical trials of 11␤-HSD1 inhibitors would be a prudent measure. 
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